DuPont Nutrition & Biosciences to highlight unique portfolio, vital expertise and enhanced commitment to meeting customer needs across the organization
Wilmington, October 07, 2020: DuPont announced it will participate in the virtual CPhI: Festival of Pharma, highlighting its commitment to meet customers’ needs for essential innovations to address the challenges of the COVID-19 global pandemic.
DuPont’s technical leaders will draw upon their decades of cellulosic and vital pharmaceutical expertise to showcase their innovation —from enabling topical trends to enhancing global focus on customer needs—during the virtual event October 5th-16th.
Specifically, DuPont experts will discuss:
- A broad, unique portfolio:DuPont pioneered leading brands like Avicel® and METHOCEL™,cellulosics with extensive track records of innovation and reliable performance. Beyond these products, we offer a variety of unique excipients that deliver functional benefits, efficiency, and cost-saving opportunities across a multitude of dosage forms and applications. In addition, DuPont offers a unique portfolio for dietary supplements, including plant-based ingredients that outperform as well as probiotics with health benefits backed by clinical science.
- Reinforcing the DuPont commitment to strategic, high-quality customer service through the implementation of Big Q, or a Quality culture, which improves all aspects and contact points for customers – from administrative processes to customer service, logistics and more. Register for the CPhI Festival of Pharma podcast for an interview with global quality leader, Pharma Solutions, Kieran O’Dwyer.
- Penchant for problem-solving: Using our deep polymer and application expertise, we can tailor attributes of our excipients to deliver on trends and unique applications.
- DuPont has worked on a unique polymer formulation that enables continuous manufacturing of controlled release tablets,which equips customers to switch from batch manufacturing, saving both time and money, while improving flow and compressibility. Learn more about how our unique portfolio delivers in this case study.
Sustainably sourcedanti-reflux solutions derived from brown seaweed can combat GERD (gastroesophageal reflux disease/acid reflux disease) by creating a raft that block stomach acids. Attendees can learn more about how our gelling alginates enable anti-reflux systems via DuPont’s case study.
In addition, DuPont is sponsoring and presenting at the Keynote: The Landscape of Affordable Healthcare with Dr. Scott Gottlieb, former Commissioner of the FDA. Through its work with IPEC (International Pharmaceutical Excipients Council), DuPont seeks to help customers navigate the complex regulatory landscape while pushing for more advanced excipient guidelines to support speed-to-market for essential drugs.
“We’re thrilled to showcase how our deep technical expertise, combined with our broad portfolio and a commitment to continuous improvement, can help play a role in meeting the opportunities the industry is facing today and in the future,” Rina Chokshi, global commercial marketing leader. “By actively collaborating with our customers, we’re helping them create the high-quality medications that are desperately needed right now.”
To learn more about the broad product portfolio or expertise areas from DuPont Nutrition & Biosciences, visit pharma.dupont.com.
Corporate Comm India (CCI Newswire)
